Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04534-z, published online 23 July 2026.
Christopher J. Sayed
United States
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Christopher J. Sayed
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
|
By Martina L. Porter, Antonio Martorell, Christopher J. Sayed, Falk G Bechara, Hadar Lev-Tov, Jennifer L. Hsiao, John Frew, Ziad Reguiai, Melinda Gooderham, Noah Goldfarb, Hessel H Van der Zee, Veronique del Marmol, Angelo V. Marzano, Benjamin D. Ehst, Lindsay S. Ackerman, Koremasa Hayama, Jennifer Kelley, Joslyn S. Kirby, Kurt Brown, Leandro Santos, Christos C. Zouboulis, Chenwei Tian, Huiling Zhen
|
Nature
Verified
Abstract Although therapeutic options for hidradenitis suppurativa (HS) continue to expand, unmet needs remain substantial. We evaluated the efficacy and safety of povorcitinib (an oral, highly selective Janus kinase 1 (JAK1) inhibitor) in patients with moderate to severe HS in two randomized trials. STOP-HS1 and STOP-HS2 were identically designed, randomized, double-blind, placebo-controlled phase 3 trials.
IgA autoantibodies promote inflammation, Th17 polarization and fibrotic responses in hidradenitis suppurativa
Abstract Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with complex immune dysregulation. While previous studies have reported tertiary lymphoid structures (TLS) and IgA-producing B cells in HS skin lesions, the pathogenic role of IgA autoantibodies remains insufficiently characterized. Here, we demonstrate that lesional skin from patients with HS exhibits elevated expression of IGHA1, IGHA2, and J chain, as confirmed by qPCR, immunofluorescence, and Western blot analyses.
Bimekizumab and Unmet Needs of Patients with HS, with Christopher J. Sayed, MD
At the 2025 American Academy of Dermatology (AAD) Annual Meeting, new 2-year findings on bimekizumab-bkzx (Bimzelx) demonstrated that the treatment is effective in promoting sustained disease control in those with moderate-to-severe hidradenitis suppurativa (HS), along with prevention of long-term draining tunnel damage.1 The findings were discussed in a new interview with HCPLive and Christopher J.
Everything You Need to Know About Hidradenitis Suppurativa
Even though the inflammatory skin condition hidradenitis suppurativa (HS) affects up to 1.5 million people in the United States, there has long been a scarcity of resources to help people living with the condition, their families, and even healthcare professionals who have little experience diagnosing and treating HS.
Hidradenitis Suppurativa Surgery Complication Rates
Hidradenitis Suppurativa Surgery Complication Rates Among Patients With Obesity or Diabetes or Who Smoke: A Review Abstract Importance Surgery is frequently required for hidradenitis suppurativa (HS) treatment, but the impact of common comorbidities such as obesity, diabetes, and smoking on outcomes has been sparsely studied. Observations A total of 12 studies met final inclusion criteria for investigating complication rates associated with at least 1 comorbidity.
The Successful Use of Upadacitinib as Monotherapy for Hidradenitis Suppurativa and Ulcerative Colitis in the Setting of Refractory Disease
Conflicts of Interest C.J.S. reports speaking for AbbVie and Novartis, consulting for AbbVie, Novartis, AstraZeneca, UCB, Incyte, InflaRx, Sanofi, Sandoz, Logical Images, and Sonoma Biotherapeutics, and investigator fees paid to his institution from Novartis, UCB, Incyte, and InflaRx. He is the secretary of the HS Foundation and member of the European HSF (uncompensated positions). All other authors have no conflict of interest.
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Summary Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Summary Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Clostridium difficile infection risk in patients with hidradenitis suppurativa
Research letter Funding sources: This work was supported by grant number T35-DK007386 from the National Institutes of Health. Conflicts of interest: C.S. has received honoraria as a speaker for AbbVie and Novartis; has acted as a consultant for AbbVie, Novartis, UCB and InflaRx; and has acted as an investigator for AbbVie, Novartis, Incyte, ChemoCentryx, InflaRx and UCB.
VIDEO: Hidradenitis suppurativa ‘tip of everybody’s mind’ at AAD Annual Meeting
April 15, 2022 1 min watch Source/Disclosures Source: Healio Interview Disclosures: Sayed reports serving as a speaker for AbbVie and Novartis; serving as a consultant for AbbVie, Aclaris, InflaRx, Novartis and UCB; serving as an investigator for AbbVie, Chemocentryx, Incyte, InflaRx, Novartis and UCB; and receiving a grant from AbbVie. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
VIDEO: Surgical collaboration when managing patients with hidradenitis suppurativa
April 14, 2022 1 min watch Source/Disclosures Source: Healio Interview Disclosures: Sayed reports serving as a speaker for AbbVie and Novartis; serving as a consultant for AbbVie, Aclaris, InflaRx, Novartis and UCB; serving as an investigator for AbbVie, Chemocentryx, Incyte, InflaRx, Novartis and UCB; and receiving a grant from AbbVie. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
VIDEO: Improving the office experience for patients with hidradenitis suppurativa
April 14, 2022 1 min watch Source/Disclosures Source: Healio Interview Disclosures: Sayed reports serving as a speaker for AbbVie and Novartis; serving as a consultant for AbbVie, Aclaris, InflaRx, Novartis and UCB; serving as an investigator for AbbVie, Chemocentryx, Incyte, InflaRx, Novartis and UCB; and receiving a grant from AbbVie. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
VIDEO: Advanced hidradenitis suppurativa management requires varied, creative strategies
April 12, 2022 1 min watch Source/Disclosures Source: Healio Interview Disclosures: Sayed reports serving as a speaker for AbbVie and Novartis; serving as a consultant for AbbVie, Aclaris, InflaRx, Novartis and UCB; serving as an investigator for AbbVie, Chemocentryx, Incyte, InflaRx, Novartis and UCB; and receiving a grant from AbbVie. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
Late Summer Styles for People With Psoriasis
by Cheryl Kramer Kaye Health Writer After too many months of loungewear and Zoom tops, you’ve probably been itching to get out and show off some serious summer style. And, if you’re one of the 7.5 million adults in the U.S. who are living with another type of itch—from a psoriasis (PsO) flare—these are the looks you’ll want to wear to protect your skin and maintain crowd cred among the fashion-forward.
Skin-Sensitive Products for Psoriasis
by Krista Bennett DeMaio Health Writer When you have psoriasis, a condition marked by skin inflammation and scaly, raised plaques, the products you put on your skin can feel irritating and possibly even trigger a flare of symptoms. The recommendation is to keep your products simple, says Sandy Skotnicki, M.D., an assistant professor in the department of dermatology at the University of Toronto in Canada.
Best Psoriasis-Comment Comebacks
by Kaleigh Fasanella Health Writer If you have psoriasis, you know firsthand the challenges of receiving unsolicited comments about your spots. In some cases, folks are just curious, but certain remarks can be callous, rude, and even hurtful. Arming yourself with solid “comebacks” can help you feel ready if and when this situation arises. Take a look at the options here, courtesy of several awesome psoriasis warriors who know what’s up.
How to Exercise With Hidradenitis Suppurative
Managing HS is risky business, especially when a solution—like regular exercise—comes with its own set of issues.
Surgery is an essential aspect of managing patients with hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a complex and heterogeneous disease for which a variety of medical and surgical treatments have been advocated. A unique and defining feature of HS is the presence of scarring and tunneling in advanced disease, which are often recalcitrant to medical therapy alone. In many cases, these tunnels are lined by stratified squamous epithelium ( Fig 1), which is similar to what is found in follicular cysts.
Multidisciplinary Update on Genital Hidradenitis Suppurativa
Abstract Importance Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a predilection for the genital region. Genital HS requires medical and surgical management as well as close collaboration among a multidisciplinary team. Observations Hidradenitis suppurativa is a disease of the hair follicles that results in recurrent nodules, abscesses, and tunneling sinus tracts.
Guide to Hidradenitis Suppurativa Treatments
If you've been diagnosed with hidradenitis suppurativa (HS), you're probably wondering, "What can I do to feel normal again?” The good news is that this chronic (meaning lifelong) skin condition can be managed so you reduce the pain and discomfort of the oozing bumps that appear under the skin, usually in the armpits, genitals, groin, buttocks, or under breasts. But there’s no cure for this disease—or even an explanation as to what is causing those lumps to appear in the first place.
Real Patients Share Their Stories
At first, hidradenitis (HS) doesn’t seem like it should be that bad. Who hasn’t had an ingrown hair now and then under their arm or in their groin? But HS isn’t anything like those once-in-blue-moon lumps. This chronic inflammatory condition causes recurrent, painful bumps (and eventually boils) that can seriously interfere with movement and cause significant scarring.
Bruising and Hemorrhagic Vesicles on the Tongue
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Christopher J.
Contact Christopher J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack